Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments and Licenses - Acquisition Narrative (Details)

v3.8.0.1
Acquisitions, Investments and Licenses - Acquisition Narrative (Details)
$ / shares in Units, $ in Millions
1 Months Ended
Aug. 31, 2016
USD ($)
$ / shares
shares
Common Stock  
Business Acquisition [Line Items]  
Stock price per share (in dollars per share) | $ / shares $ 9.10
Transition Therapeutics  
Business Acquisition [Line Items]  
Consideration transferred | $ $ 58.5
Transition Therapeutics | Common Stock  
Business Acquisition [Line Items]  
Common stock received (in shares) | shares 6,431,899